-
Ascenzi P, Bocedi A, Heptonstall J, Capobianchi MR, Di Caro A, Mastrangelo E, Bolognesi M, Ippolito G, 2008: Ebolavirus and Marburgvirus: insight the Filoviridae family[J]. Mol Aspects Med, 29, 151-185. doi: 10.1016/j.mam.2007.09.005
-
Audet J, Wong G, Wang H, Lu G, Gao GF, Kobinger G, Qiu X, 2014: Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus[J]. Sci Rep, 4, 6881-. doi: 10.1038/srep06881
-
Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, Xu RH, Zhou B, Lu H, Kwilas SA, Hahn TJ, Kpamegan E, Hooper J, Carrion R, J r., Glenn G, Smith G, 2016: Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice[J]. Vaccine, 34, 1927-1935. doi: 10.1016/j.vaccine.2016.02.033
-
Bhattacharyya S, Hope TJ, 2011: Full-length Ebola glycoprotein accumulates in the endoplasmic reticulum[J]. Virol J, 8, 11-. doi: 10.1186/1743-422X-8-11
-
Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A, 2007: Successful topical respiratory tract immunization of primates against Ebola virus[J]. J Virol, 81, 6379-6388. doi: 10.1128/JVI.00105-07
-
Das D, Jacobs F, Feldmann H, Jones SM, Suresh MR, 2007: Differential expression of the Ebola virus GP(1, 2) protein and its fragments in E[J]. coli. Protein Expr Purif, 54, 117-125. doi: 10.1016/j.pep.2007.02.004
-
Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, Kahnt J, Stroher U, Klenk HD, Volchkov V, 2004: Ectodomain shedding of the glycoprotein GP of Ebola virus[J]. EMBO J, 23, 2175-2184. doi: 10.1038/sj.emboj.7600219
-
Elliott LH, Sanchez A, Holloway BP, Kiley MP, McCormick JB, 1993: Ebola protein analyses for the determination of genetic organization[J]. Arch Virol, 133, 423-436. doi: 10.1007/BF01313780
-
Falzarano D, Krokhin O, Wahl-Jensen V, Seebach J, Wolf K, Schnittler HJ, Feldmann H, 2006: Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus[J]. Chembiochem, 7, 1605-1611. doi: 10.1002/cbic.v7:10
-
Favier AL, Gout E, Reynard O, Ferraris O, Kleman JP, Volchkov V, Peyrefitte C, Thielens NM, 2016: Enhancement of Ebola virus infection via ficolin-1 interaction with the mucin domain of GP glycoprotein[J]. J Virol, 90, 5256-5269. doi: 10.1128/JVI.00232-16
-
Feldmann H, Jones S, Klenk HD, Schnittler HJ, 2003: Ebola virus: from discovery to vaccine[J]. Nat Rev Immunol, 3, 677-685. doi: 10.1038/nri1154
-
Hartlieb B, Weissenhorn W, 2006: Filovirus assembly and budding[J]. Virology, 344, 64-70. doi: 10.1016/j.virol.2005.09.018
-
Jasenosky LD, Kawaoka Y, 2004: Filovirus budding[J]. Virus Res, 106, 181-188. doi: 10.1016/j.virusres.2004.08.014
-
Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y, 2001: Ebola virus VP40-induced particle formation and association with the lipid bilayer[J]. J Virol, 75, 5205-5214. doi: 10.1128/JVI.75.11.5205-5214.2001
-
Johnson RF, Bell P, Harty RN, 2006: Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology[J]. Virol J, 3, 31-. doi: 10.1186/1743-422X-3-31
-
Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW, 2005: Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses[J]. Nat Med, 11, 786-790. doi: 10.1038/nm1258
-
Kuhl A, Hoffmann M, Muller MA, Munster VJ, Gnirss K, Kiene M, Tsegaye TS, Behrens G, Herrler G, Feldmann H, Drosten C, Pohlmann S, 2011: Comparative analysis of Ebola virus glycoprotein interactions with human and bat cells[J]. J Infect Dis, 204, S840-S849. doi: 10.1093/infdis/jir306
-
Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO, 2008: Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor[J]. Nature, 454, 177-182. doi: 10.1038/nature07082
-
Lee JE, Saphire EO, 2009a: Ebolavirus glycoprotein structure and mechanism of entry[J]. Future Virol, 4, 621-635. doi: 10.2217/fvl.09.56
-
Lee JE, Saphire EO, 2009b: Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it[J]. Curr Opin Struct Biol, 19, 408-417. doi: 10.1016/j.sbi.2009.05.004
-
Li D, Chen T, Hu Y, Zhou Y, Liu Q, Zhou D, Jin X, Huang Z, 2016: An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions[J]. J Virol, 90, 8720-8728. doi: 10.1128/JVI.01239-16
-
Licata JM, Johnson RF, Han Z, Harty RN, 2004: Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles[J]. J Virol, 78, 7344-7351. doi: 10.1128/JVI.78.14.7344-7351.2004
-
Melito PL, Qiu X, Fernando LM, deVarennes SL, Beniac DR, Booth TF, Jones SM, 2008: The creation of stable cell lines expressing Ebola virus glycoproteins and the matrix protein VP40 and generating Ebola virus-like particles utilizing an ecdysone inducible mammalian expression system[J]. J Virol Methods, 148, 237-243. doi: 10.1016/j.jviromet.2007.12.004
-
Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, Saikh KU, Heidebrink KD, Jahrling PB, Ulrich RG, Schmaljohn CS, 2003: Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs[J]. Virus Res, 92, 187-193. doi: 10.1016/S0168-1702(02)00338-6
-
Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y, 2002: Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP[J]. J Virol, 76, 4855-4865. doi: 10.1128/JVI.76.10.4855-4865.2002
-
Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF, 2000: Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus[J]. Vaccine, 19, 142-153. doi: 10.1016/S0264-410X(00)00113-4
-
Sanchez A, Kiley MP, Holloway BP, Auperin DD, 1993: Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus[J]. Virus Res, 29, 215-240. doi: 10.1016/0168-1702(93)90063-S
-
Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmit J, Jahrling PB, Nabel GJ, 2006: Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs[J]. PLoS Med, 3, e177-. doi: 10.1371/journal.pmed.0030177
-
Sullivan NJ, Peterson M, Yang ZY, Kong WP, Duckers H, Nabel E, Nabel GJ, 2005: Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway[J]. J Virol, 79, 547-553. doi: 10.1128/JVI.79.1.547-553.2005
-
Sun Y, Carrion R, J r., Ye L, Wen Z, Ro YT, Brasky K, Ticer AE, Schwegler EE, Patterson JL, Compans RW, Yang C, 2009: Protection against lethal challenge by Ebola virus-like particles produced in insect cells[J]. Virology, 383, 12-21. doi: 10.1016/j.virol.2008.09.020
-
Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S, 2005: Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections[J]. Vaccine, 23, 3033-3042. doi: 10.1016/j.vaccine.2004.11.070
-
Volchkov VE, Feldmann H, Volchkova VA, Klenk HD, 1998: Processing of the Ebola virus glycoprotein by the proprotein convertase furin[J]. Proc Natl Acad Sci U S A, 95, 5762-5767. doi: 10.1073/pnas.95.10.5762
-
Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S, 2003: Ebola virus-like particles protect from lethal Ebola virus infection[J]. Proc Natl Acad Sci U S A, 100, 15889-15894. doi: 10.1073/pnas.2237038100
-
Warfield KL, Posten NA, Swenson DL, Olinger GG, Esposito D, Gillette WK, Hopkins RF, Costantino J, Panchal RG, Hartley JL, Aman MJ, Bavari S, 2007a: Filovirus-like particles produced in insect cells: Immunogenicity and protection in rodents[J]. Journal of Infectious Diseases, 196, S421-S429. doi: 10.1086/525008
-
Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S, 2007b: Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge[J]. J Infect Dis, 196, S430-S437. doi: 10.1086/525008
-
Ye L, Lin J, Sun Y, Bennouna S, Lo M, Wu Q, Bu Z, Pulendran B, Compans RW, Yang C, 2006: Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies[J]. Virology, 351, 260-270. doi: 10.1016/j.virol.2006.03.021
-
Zampieri CA, Fortin JF, Nolan GP, Nabel GJ, 2007: The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity[J]. J Virol, 81, 1230-1240. doi: 10.1128/JVI.01586-06